LQDA
Price
$55.21Alerts
Change
+$3.81 (+7.41%)
Updated
Nov 11 closing price
Capitalization
3.97B
127 days until earnings call
Intraday BUY SELL Signals
UNCY
Price
$3.78Alerts
Change
+$0.12 (+3.28%)
Updated
Nov 11 closing price
Capitalization
98.89M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

LQDA vs UNCY

LQDA vs UNCY Comparison Chart in %
View a ticker or compare two or three
VS
LQDA vs. UNCY commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LQDA is a Buy and UNCY is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LQDA with price predictions
Nov 10, 2026

LQDA's RSI Oscillator ascends from oversold territory

The RSI Indicator for LQDA moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LQDA as a result. In 70 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.

LQDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +15.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 280 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 200 of 247 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 55 of 68 cases where LQDA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

The 50-day moving average for LQDA moved below the 200-day moving average on October 28, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

LQDA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.369) is normal, around the industry mean (6.379). P/E Ratio (28.101) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
a Summary for UNCY with price predictions
Nov 10, 2026

Momentum Indicator for UNCY turns positive, indicating new upward trend

UNCY saw its Momentum Indicator move above the 0 level on November 09, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 100 similar instances where the indicator turned positive. In 86 of the 100 cases, the stock moved higher in the following days. The odds of a move higher are at 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UNCY's RSI Oscillator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 72 cases where UNCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for UNCY just turned positive on October 22, 2026. Looking at past instances where UNCY's MACD turned positive, the stock continued to rise in 39 of 48 cases over the following month. The odds of a continued upward trend are 81%.

Following a +6.32% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNCY advanced for three days, in 209 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for UNCY entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.856) is normal, around the industry mean (3.498). P/E Ratio (-2.029) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (39.216) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. UNCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
LQDA: Fundamental Ratings
LQDA
OUTLOOK RATING
1..100
47
VALUATION
overvalued / fair valued / undervalued
1..100
75
Overvalued
PROFIT vs RISK RATING
1..100
54
SMR RATING
1..100
12
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
28

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LQDAUNCY
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
76%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (LQDA: $51.40 vs. UNCY: $3.66)
Brand notoriety: LQDA and UNCY are both not notable
LQDA represents the Pharmaceuticals: Generic, while UNCY is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: LQDA: 54% vs. UNCY: 55%
Market capitalization -- LQDA: $3.97B vs. UNCY: $98.89M
LQDA [@Pharmaceuticals: Generic] is valued at $3.97B. UNCY’s [@Biotechnology] market capitalization is $98.89M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LQDA’s FA Score shows that 1 FA rating(s) are green while UNCY’s FA Score has 1 green FA rating(s).

  • LQDA’s FA Score: 1 green, 4 red.
  • UNCY’s FA Score: 1 green, 4 red.
According to our system of comparison, LQDA is a better buy in the long-term than UNCY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LQDA’s TA Score shows that 6 TA indicator(s) are bullish while UNCY’s TA Score has 5 bullish TA indicator(s).

  • LQDA’s TA Score: 6 bullish, 4 bearish.
  • UNCY’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, UNCY is a better buy in the short-term than LQDA.

Price Growth

LQDA (@Pharmaceuticals: Generic) experienced а +21.80% price change this week, while UNCY (@Biotechnology) price change was +1.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.20%. For the same industry, the average monthly price growth was -6.54%, and the average quarterly price growth was +10.31%.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

LQDA is expected to report earnings on Mar 18, 2027.

UNCY is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.20% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with UNCY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then UNCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
+7.37%
UNCY - LQDA
34%
Loosely correlated
-1.08%
GOSS - LQDA
34%
Loosely correlated
+5.97%
VIR - LQDA
32%
Poorly correlated
-3.63%
KROS - LQDA
32%
Poorly correlated
+1.74%
MNKD - LQDA
32%
Poorly correlated
+0.95%
More

UNCY and

Correlation & Price change

A.I.dvisor indicates that over the last year, UNCY has been loosely correlated with NVCT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if UNCY jumps, then NVCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UNCY
1D Price
Change %
UNCY100%
-1.08%
NVCT - UNCY
51%
Loosely correlated
+0.29%
ICU - UNCY
46%
Loosely correlated
-3.06%
VTGN - UNCY
44%
Loosely correlated
-0.70%
OBIO - UNCY
35%
Loosely correlated
+0.53%
LQDA - UNCY
34%
Loosely correlated
+7.37%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACSI78.09N/A
N/A
American Customer Satisfaction ETF (ACSI)
OBOR26.00N/A
N/A
KraneShares MSCI One Belt One Road Index ETF (OBOR)
CBON24.13-0.03
-0.10%
VanEck China Bond ETF (CBON)
GAUG41.82-0.12
-0.28%
FT Vest U.S. Equity Moderate Buffer ETF - August (GAUG)
GOF9.11-0.08
-0.87%
Guggenheim Strategic Opportunities Fund